The Efficacy and Safety of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 368 participants.

Also called NCT02008682

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 368 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02008682
Other papers using this trial's data
  • Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26-week, open-label, randomized, active comparator clinical trial Diabetes, obesity & metabolism, 2016-08 DOI, PubMed 27060930, PMC5084818 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02008682. Randomized; no masking; primary purpose treatment. Start 2013-12 (registry gives no type); primary completion 2014-11 (actual). Results posted on 2015-12-22.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Efficacy and Safety of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes
Condition
Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
liraglutide
Intervention (Drug)
sitagliptin
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct02008682
Content hash
18a4b05240486b0daff2415c058874f923c2f82eb969602fbf26f02f65bf4440